Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Dendreon Corporation    DNDNQ   US24823Q1076

DENDREON CORPORATION (DNDNQ)

24
Delayed Quote. Delayed Nasdaq - 03/31 03:56:53 pm
0.039 USD   -2.50%
02/20DJValeant Approved to Buy Dendreon Assets for $495 Million
02/20 Drugmaker Valeant close to buying Salix - source
02/12 VALEANT SECURES : Bloomberg
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201120122013201420152016
Sales214326284299317335
Operating income (EBITDA)-255-300-212-82,0-8,9834,3
Operating profit (EBIT)-292-340-243-57,0-56,835,3
Pre-Tax Profit (EBT)-338-394-297---
Net income-338-394-297-107-73,1-22,2
EPS ( $)-2,31-2,65-1,95-0,50-0,36-0,14
Dividend per Share ( $)------
Yield------
Announcement Date02/27/2012
01:30pm
02/25/2013
12:30pm
03/03/2014
12:30pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201120122013201420152016
Debt109372494-421377
Finance------
Operating income (EBITDA)-255-300-212-82,0-8,9834,3
Leverage
(Debt/EBITDA)
-0,43x-1,24x-2,33x--46,9x11,0x
Capital Expenditure25,418,85,626,007,00-
Book Value Per Share (BVPS)2,36 $0,22 $-1,57 $--1,68 $-1,38 $
Cash Flow per Share-1,66 $-1,40 $-1,43 $--0,05 $0,12 $
Announcement Date02/27/2012
01:30pm
02/25/2013
12:30pm
03/03/2014
12:30pm
---
Balance Sheet Analysis
Assessed data source :
© 2015 Thomson Reuters
Advertisement
Financial Ratios

Size 2014e 2015e
Capitalization 6,19 M$ -
Entreprise Value (EV) - 427 M$
Valuation 2014e 2015e
PER (Price / EPS)
Capitalization / Revenue 0,02x 0,02x
EV / Revenue - -
EV / EBITDA - -
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -0,02x
Profitability 2014e 2015e
Operating Margin (EBIT / Sales) -19,1% -17,9%
operating Leverage (Delta EBIT / Delta Sales) 14,5x 0,04x
Net Margin (Net Profit / Revenue) -36,0% -23,0%
ROA (Net Profit / Asset) -20,9% -9,50%
ROE (Net Profit / Equities) 102% -5,47%
Rate of Dividend - -
Balance Sheet Analysis 2014e 2015e
CAPEX / Sales   2,01% 2,20%
Cash Flow / Sales (Taux d'autofinancement) - -2,65%
Capital Intensity (Assets / Sales) 1,72x 2,42x
Financial Leverage (Net Debt / EBITDA) - -46,9x
EPS & Dividend
Dynamic quotes  
ON
| OFF